S-F Hsu Schmitz
Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess U, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leukemia & lymphoma 2009:1-11.
04.08.2009Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98)
04.08.2009Leukemia & lymphoma 2009:1-11
Zenhausern R, Rufener B, Bargetzi M, Leoncini L, Hess Urs, Meyer-Monard S, Heim D, Solenthaler M, Schmitz S-F Hsu, Tobler A
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82.
01.10.2005Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.10.2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82
Ghielmini M, Cerny Thomas, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S-F Hsu